Clear Labs announced a new automated workflow featuring Pillar Biosciences' SLIMamp® chemistry on the Clear Dx™ platform, debuting at the AMP Annual Meeting. The collaboration expands Clear Labs' automation technology into oncology, enabling streamlined, end-to-end NGS workflows for Pillar's oncoReveal® assays with early access beginning November 2025.
SAN CARLOS, Calif., Nov. 13, 2025 /PRNewswire-PRWeb/ -- Clear Labs, a leader in fully automated next-generation sequencing (NGS) solutions, today announced the introduction of a new automated workflow featuring Pillar Biosciences' SLIMamp® chemistry on the Clear Dx™ platform. The NGS workflow will debut at the Association for Molecular Pathology (AMP) Annual Meeting in Boston.
The integrated NGS workflow within Clear Labs' fully automated NGS platform leverages the simple core chemistry that underpins Pillar's portfolio of oncoReveal® assays and enables laboratories to perform streamlined, end-to-end oncology workflows with reduced hands-on time and standardized automation. The Clear Dx platform is offered for Pillar's oncoReveal Solid Tumor 22 Gene Research Use Only (RUO) panel, with early-access availability beginning November 2025.
"This milestone marks an exciting expansion of our automation technology into oncology applications," said Sasan Amini, PhD, Founder and CEO of Clear Labs. "By integrating Pillar's trusted NGS chemistry with the Clear Dx platform, we are helping laboratories explore efficient, scalable approaches to complex genomic workflows."
"We are pleased to collaborate with Clear Labs to extend the reach of our technology and kitted assay portfolio through automation," said Daniel Harma, Chief Commercial Officer, Pillar Biosciences. "This initiative demonstrates our shared commitment to innovation and to enabling laboratories with more accessible, standardized NGS solutions."
This new workflow will expand Clear Labs' portfolio into oncology as the company builds on its success in delivering automated NGS solutions for infectious disease applications.
About Clear Labs
Clear Labs is a pioneer in fully automated next-generation sequencing (NGS) solutions spanning oncology and infectious disease applications. With a focus on simplicity, speed, and precision, Clear Labs empowers laboratories to bring advanced genomics in-house, reducing reliance on send-outs and enabling consistent, high-quality results.
About Pillar Biosciences
Pillar Biosciences is the leader in Decision Medicine™, which is the utilization of highly accurate and sensitive next-generation sequencing (NGS) testing technology to generate data that optimizes selection of precision therapies for cancer patients, from tumor profiling to therapy selection, and recurrence monitoring. Pillar's NGS testing solutions are powered by its proprietary SLIMamp® and PiVAT® technologies, helping to localize the testing process, reduce diagnostic costs and improve access and efficiency of complex NGS testing for clinicians, prescribers, and patients globally. The company has more than 20 NGS testing kits available in IVD or RUO formats, with multiple panels in various stages of development. Pillar Biosciences has operations in Natick, MA. For more information visit pillarbiosci.com and connect with us on LinkedIn.
For Research Use Only. Not for use in diagnostic procedures.
For more information, visitwww.clearlabs.com.
Media Contact
Kyle Rhoden, Clear Labs, 1 650.257.3304, [email protected], www.clearlabs.com
SOURCE Clear Labs
Share this article